Opthea’s (OPT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Opthea (NASDAQ:OPT) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

Separately, Canaccord Genuity Group upgraded shares of Opthea to a “strong-buy” rating in a research report on Tuesday, December 17th.

Opthea Trading Up 1.4 %

Shares of OPT stock opened at $5.07 on Wednesday. Opthea has a 1 year low of $1.79 and a 1 year high of $5.45. The stock has a fifty day moving average of $3.74 and a two-hundred day moving average of $3.53.

Institutional Trading of Opthea

An institutional investor recently bought a new position in Opthea stock. Twin Lakes Capital Management LLC purchased a new position in Opthea Limited (NASDAQ:OPT) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 19,806 shares of the company’s stock, valued at approximately $81,000. 55.95% of the stock is currently owned by institutional investors.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.